Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

AbbVie reports Phase III psoriasis data for IL-23 mAb risankizumab

October 27, 2017 9:40 PM UTC

AbbVie Inc. (NYSE:ABBV) said risankizumab (BI 655066) met the co-primary and all ranked secondary endpoints in 3 double-blind, international Phase III trials to treat moderate to severe chronic plaque psoriasis. The company did not respond to inquiries regarding next steps for the humanized IgG1 mAb that binds and neutralizes the p19 subunit of IL-23.

In the identical ultIMMa-1 and ultIMMa-2 trials, subcutaneous risankizumab led to ≥90% skin clearance as measured by the Psoriasis Area and Severity Index (PASI 90) at week 16, the first co-primary endpoint, in 75% of patients vs. 5% and 2% for placebo, respectively. In the same trials, 42% and 48% of patients receiving Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ) achieved a PASI 90 response. On the second co-primary endpoint, risankizumab led to static Physician’s Global Assessment (sPGA) scores of clear or almost clear at week 16 in 88% and 84% of patients in ultIMMa-1 and ultIMMa-2, respectively, vs. 8% and 5% for placebo and 63% and 62% for Stelara. Patients received risankizumab at weeks 0 and 4 and then every 12 weeks...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article